135682-55-2

Basic information

• Product Name: [(1R,2R,3R,4S)-3-(2-{3-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-propyl}-benzyl)-7-oxa-bicyclo[2.2.1]hept-2-yl]-methanol
• Synonyms: [(1R,2R,3R,4S)-3-(2-{3-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-propyl}-benzyl)-7-oxa-bicyclo[2.2.1]hept-2-yl]-methanol
• CAS NO: 135682-55-2
• Molecular Weight: 418.692
• Mol File: 135682-55-2.mol

Chemical Properties

• CAS DataBase Reference: [(1R,2R,3R,4S)-3-(2-{3-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-propyl}-benzyl)-7-oxa-bicyclo[2.2.1]hept-2-yl]-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: [(1R,2R,3R,4S)-3-(2-{3-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-propyl}-benzyl)-7-oxa-bicyclo[2.2.1]hept-2-yl]-methanol(135682-55-2)
• EPA Substance Registry System: [(1R,2R,3R,4S)-3-(2-{3-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-propyl}-benzyl)-7-oxa-bicyclo[2.2.1]hept-2-yl]-methanol(135682-55-2)

Safety Data

• Hazardous Substances Data: 135682-55-2(Hazardous Substances Data)

Upstream product

• 6630-33-7 ortho-bromobenzaldehyde 
• 133027-56-2 <3-(2-bromophenyl)propoxy>dimethyl(1,1,2-trimethylpropyl)silane 
• 102540-15-8 methyl (2E)-3-(2-bromophenyl)-2-propenoate 
• 52221-92-8 3-(2-bromo-phenyl)-propan-1-ol 
• 66191-86-4 3-(2-bromophenyl)propanoic acid,methyl ester 
• 142663-80-7 <1-bromo-2-<3-<oxy>propyl>phenyl>magnesium 
• 404575-34-4 7-oxabicyclo<2.2.1>heptane tetrahydrofuranol 
• 135682-54-1 <1S-(1α,2α,3α,(S^*),4α)>-α-<2-<3-<oxy>propyl>phenyl>-7-oxabicyclo<2.2.1>heptane-2,3-dimethanol 
• 133027-57-3 [1S-(1α,2α,3α,4α)]-α-[2-[3-[[Dimethyl-(1,1,2-trimethylpropyl)silyl]oxy]propyl]phenyl]-7-oxabicyclo[2.2.1]heptane-2,3-dimethanol 

Downstream Products

• 135613-49-9 (1R,2S,3R,4S)-3-[2-(3-formyl-7-oxabicyclo[2.2.1]hept-2-yl-methyl)phenyl]propionic acid methyl ester 
• 135613-44-4 <1S-1α,2α,3α,4α>-2-<<3-(hydroxymethyl)-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenebutanoic acid, methyl ester 
• 135613-46-6 3-{2-[(1S,2R,3R,4R)-3-(tert-Butyl-dimethyl-silanyloxymethyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl]-phenyl}-propionic acid 
• 135613-45-5 3-{2-[(1S,2R,3R,4R)-3-(tert-Butyl-dimethyl-silanyloxymethyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl]-phenyl}-propionic acid methyl ester 
• 135613-47-7 4-{2-[(1S,2R,3R,4R)-3-(tert-Butyl-dimethyl-silanyloxymethyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl]-phenyl}-1-diazo-butan-2-one 
• 135613-48-8 4-{2-[(1S,2R,3R,4R)-3-(tert-Butyl-dimethyl-silanyloxymethyl)-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl]-phenyl}-butyric acid methyl ester 
• 135613-50-2 C₂₅H₂₉N₃O₄ 
• 135613-37-5 <1S-1α,2α,3α,4α>-2-<<3-<<<(phenylamino)carbonyl>hydrazono>methyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenebutanoic acid 
• 135682-58-5 syn-<1S-1α,2α,3α,4α>-2-<<3-<<<(phenylamino)carbonyl>hydrazono>methyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid 
• 135613-36-4 anti-<1S-1α,2α,3α,4α>-2-<<3-<<<(phenylamino)carbonyl>hydrazono>methyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid 
• 142757-92-4 <1S-(1α,2α,3α,4α)>-2-<<3-<<<1-(hydroxymethyl)-2-oxo-2-(phenylmethoxy)ethyl>amino>carbonyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid methyl ester 
• 142757-94-6 <1S-(1α,2α,3α,4α)>-2-<<3-<4-<(phenylmethoxy)carbonyl>-2-oxazolyl>-7-oxabicyclo<2.2.1>hept-2-yl>methyl>benzenepropanoic acid methyl ester 
• 149079-66-3 3-(2-{(1S,2R,3S,4R)-3-[4-(4-Cyclohexyl-butylcarbamoyl)-oxazol-2-yl]-7-oxa-bicyclo[2.2.1]hept-2-ylmethyl}-phenyl)-propionic acid benzyl ester 
• 149079-67-4 2-{(1R,2S,3R,4S)-3-[2-(2-Benzyloxycarbonyl-ethyl)-benzyl]-7-oxa-bicyclo[2.2.1]hept-2-yl}-oxazole-4-carboxylic acid 4-cyclohexyl-butyl ester 

Relevant articles and documents

Interphenylene 7-Oxabicycloheptane Oxazoles. Highly Potent, Selective, and Long-Acting Thromboxane A2 Receptor Antagonists

A series of interphenylene 7-oxabicycloheptane oxazoles (2) were prepared and evaluated for their thromboxane (TxA2) antagonistic activity in vitro and duration of action in vivo.Examination of the carboxyl side chain indicated that the

Interphenylene 7-oxabicyclo[2.2.1]heptane thromboxane A2 antagonists. Semicarbazone ω-chains

A series of chiral interphenylene 7-oxabicyclo[2.2.1]heptane semicarbazones 19-26 were prepared and evaluated for their in vitro thromboxane (TxA2) antagonistic activity and in vivo duration of action. The potency of 19-26 was found to be highly dependent on the substitution pattern of the interphenylene ring and decreased in the order ortho > meta >> para. SQ 35,091 (25), [1S-(1α,2α,3α,4α)]-2-[[3-[[[(phenylamino)carbonyl]hydrazono] methyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, was identified as a potent and long-acting TxA2 antagonist. In human platelet rich plasma SQ 35,091 inhibited arachidonic acid (800 μM) and U-46,619 (10 μM) induced aggregation with I50 values of 3 and 12 nM, respectively. In contrast, no inhibition of ADP (20 μM) induced aggregation was observed at >1000 μM. Receptor binding studies with [3H]-SQ 29,548 showed SQ 35,091 was a competitive antagonist with a K(d) value of 1.0 ± 0.1 nM in human platelet membranes. In vivo SQ 35,091 (0.2 mg/kg po) showed extended protection (T50 = 16 h) from U-46,619 (2 mg/kg iv) induced death in mice. These compounds have for the first time demonstrated that a metabolically stable interphenylene α-sidechain can be introduced into a prostanoid-like series of TxA2 antagonists with the maintenance of potent antagonistic activity.